The role of NF-κB/IκB proteins in cancer: Implications for novel treatment strategies

Surgical Oncology

Volumn 8, Issue 3, 1999, Pages 143-153

  Schwartz, Stephanie A ^a   Hernandez, Ambrosio ^a   Mark Evers, B ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Apoptosis; Cancer biology; NF B; Transcription factors

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ANTISENSE OLIGONUCLEOTIDE; BENZYLOXYCARBONYLISOLEUCYL(O TERT BUTYLGLUTAMYL)ALANYLLEUCINAL; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYTOKINE; DEXAMETHASONE; DISULFIRAM; DITHIOCARBAMIC ACID DERIVATIVE; E1A PROTEIN; GLUCOCORTICOID; I KAPPA B; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; LACTACYSTIN; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOTIDE DERIVATIVE; PROTEASOME INHIBITOR; PYRROLIDINE DITHIOCARBAMATE; SALICYLATE SODIUM; SALICYLIC ACID DERIVATIVE; SN 50; SULINDAC; SYNTHETIC PEPTIDE; TRANSCRIPTION FACTOR DECOY; UNCLASSIFIED DRUG; VIRUS PROTEIN; CYSTEINE PROTEINASE; MULTIENZYME COMPLEX; PROTEASOME; STEROID;

APOPTOSIS; ARTICLE; BLADDER CARCINOMA; BREAST CARCINOMA; CACHEXIA; CANCER GROWTH; CANCER RESEARCH; CARCINOGENESIS; CELL ADHESION; CELL CYCLE; CELL SURVIVAL; COLON CARCINOMA; DRUG SENSITIZATION; DRUG TARGETING; HUMAN; MELANOMA; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN FAMILY; RADIOSENSITIZATION; SOLID TUMOR; THYROID CARCINOMA; TRANSCRIPTION REGULATION; COCARCINOGENESIS; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; INFLAMMATION; MOLECULAR BIOLOGY; MUTATION; NEOPLASM; PHYSIOLOGY; REVIEW;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; COCARCINOGENESIS; CYSTEINE ENDOPEPTIDASES; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B PROTEINS; INFLAMMATION; MOLECULAR BIOLOGY; MULTIENZYME COMPLEXES; MUTATION; NEOPLASMS; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; STEROIDS; TRANSCRIPTION, GENETIC;

EID: 0033237348     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-7404(00)00012-8     Document Type: Review

References (92)

1. Multiple nuclear factors interact with the immunoglobulin enhancer sequences
2. Multiple signals converging on NFκB
3. NFκB: Ten years after
4. NFκB and Rel proteins: Evolutionarily conserved mediators of immune responses
5. The NFκB and IκB proteins: New discoveries and insights
6. NF-kappaB to the rescue: RELs, apoptosis and cellular transformation
7. Signal transduction through NF-κB
8. NF-κB as a frequent target for immunosuppressive and anti-inflammatory molecules
9. Activation of NF-κB by antineoplastic agents: Role of protein kinase C
10. Modulation of NF-κB, and Bcl-2 in apoptosis induced by cisplatin in HeLa cells
11. Nuclear factor-κB-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug
12. Induction of nuclear factorκB after low-dose ionizing radiation involves a reactive oxygen intermediate signaling pathway
13. Rel/NF-κB and IκB factors in oncogenesis
14. Rel/NF-κB/IκB proteins and cancer
15. Clinically relevant findings
16. Distinct combinations of NF-κB subunits determine the specificity of transcriptional activation
17. Selection of optimal κB/Rel DNA-binding motifs: Interaction of both subunits of NF-κB with DNA is required for transcriptional activation
18. Differential transcriptional activation in vitro by NF-κB/Rel proteins
19. Purification, reconstitution, and IκB association of the c-Rel-p65 (RelA) complex, a strong activator of transcription
20. Intramolecular masking of the nuclear location signal and dimerization domain in the precursor for the p50 NF-κB subunit
21. IκB interacts with the nuclear localization sequences of the subunits of NF-κB: A mechanism for cytoplasmic retention
22. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor
23. The TNF-receptor 1-associated protein TRADD signals cell death and NF-κB activation
24. The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signalling complex
25. TRAF2-mediated activation of NF-κB by TNF receptor 2 and CD40
26. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways
27. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis
28. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain
29. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex
30. RIP: A novel protein containing a death domain the interacts with Fas/APO1 (CD95) in yeast and causes cell death
31. Identification and characterization of an IκB kinase
32. A cytokine-responsive IκB kinase that activates the transcription factor NF-κB
33. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation
34. IKK-1 and IKK-1: Cytokine-activated IκB kinases essential for NF-κB activation
35. IκB kinase-β: NF-κB activation and complex formation with IκB kinase-α amd NIK
36. Phosphorylation of human IκB-α on serines 32 and 36 controls IκB-α proteolysis and NF-κB activation in response to diverse stimuli
37. Mapping of the inducible IκB phosphorylation sites that signal its ubiquitination and degradation
38. Phosphorylation of IκBα precedes but is not sufficient for its dissociation from NF-κB
39. Rapid proteolysis of IκB-α is necessary for activation of the transcription factor NF-κB
40. Signal-induced site-specific phosphorylation targets IκBα to the ubiquitin-proteasome pathway
41. Stimulation-dependent IκB phosphorylation marks the NF-κB inhibitor for degradation via the ubiquitin-proteasome pathway
42. Signal-induced degradation of IκBα requires site-specific ubiquitination
43. Inhibition of NF-κB cellular function by specific targeting of the IκB ubiquitin ligase
44. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB
45. Severe liver degeneration in mice lacking the IκB kinase 2 gene
46. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP-2 is under NF-κB control
47. NF-κB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP-1 and c-IAP-2 to suppress caspase-8 activation
48. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras
49. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB
50. IkappaB alpha overexpression in human breast carcinoma MCF7 cells inhibits nuclear factor-kappaB activation but not tumor necrosis factor-alpha-induced apoptosis
51. Efficient adenoviral transfer of NF-κB inhibitor sensitizes melanoma to tumor necrosis factor-mediated apoptosis
52. PG490 (triptolide) cooperates with tumor necrosis factor-α to induce apoptosis in tumor cells
53. An essential role for nuclear factor kappa B in preventing TNF-α-induced cell death in prostate cancer cells
54. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB
55. Induction of apoptosis with I-κB, the inhibitor of NF-κB
56. An essential role for NF-kappa B in preventing TNF-alpha-induced cell death
57. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer
58. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth
59. Enhanced degradation of I-κBα contributes to endogenous activation of NF-κB in Hs294T melanoma cells
60. Elevated constitutive IκB kinase activity and IκB-α phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-α transcription
61. Regulation of NF-κB activity by IκB-related proteins in adenocarcinoma cells
62. The nuclear factor-κB transcription factor is constitutively active in human pancreatic adenocarcinoma cells
63. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NF-κB p65 protein expression
64. Induction of apoptosis of cytokine-producing bladder cancer cells by adenovirus-mediated IκBα overexpression
65. The NF-κB transcription factor and cancer: High expression of NF-κB- and IκB-related proteins in tumor cell lines
66. Interleukin-1 increases expression of the LYT-10 (NFκB2) proto-oncogene/transcription factor in renal cell carcinoma lines
67. Altered expression of the p50 subunit of the NF-κB transcription factor complex in non-small cell lung carcinoma
68. A novel NF-κB p65 spliced transcript lacking exons 6 and 7 in a non-small cell lung carcinoma cell line
69. Innovative treatment programs against cancer II. Nuclear factor-κB (NF-κB) as a molecular target
70. Biological and biochemical inhibitors of the NF-κB/Rel proteins and cytokine synthesis
71. Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression
72. Transcription factor decoy approach to decipher the role of NF-κB in oncogenesis
73. Inhibition of nuclear factor-kappaB activity is involved in E1A-mediated sensitization of radiation-induced apoptosis
74. Enhanced radiosensitivity by inhibition of nuclear factorκB activation in human malignant glioma cells
75. Intratumoral injection of oligonucleotides to the NF-κB binding site inhibits cachexia in a mouse tumor model
76. A proteasome inhibitor prevents activation of NF-κB and stabilizes a newly phosphorylated form of IκBα that is still bound to NF-κB
77. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells
78. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin
79. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-α-initiated apoptosis
80. Degradation of E2A proteins through a ubiquitin-conjugating enzyme, UbcE2A
81. Inhibition of TNF-α-induced NF-κB activation and IL-8 release in A549 cells with the proteasome inhibitor MG-132
82. Inhibition of NFκB in activated rat hepatic stellate cells by proteasome inhibitors and an IκB super-repressor
83. In vivo ubiquitination and proteasome-mediated degradation of p53
84. Proteasome-dependent regulation of p21(WAF1/CIP1) expression
85. Dithiocarbamates are potent inhibitors of nuclear factor kappa B activation in intact cells
86. Induction of apoptosis by thiuramdisulfides, the reactive metabolites of dithiocarbamates, through coordinative modulation of NF-κB, c-fos/c-jun, and p53 proteins
87. Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB synthesis
88. Salicylates inhibit NF-κB activation and enhance TNF-alpha-induced apoptosis in human pancreatic cancer cells
89. Sulindac inhibits activation of the NF-κB pathway
90. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer
91. Inhibition of nuclear translocation of transcription factor NF-κB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence
92. Inhibition of NF-κB activity in human T lymphocytes induces caspase-dependent apoptosis without detectable activation of caspase-1 and -3